Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice

Francesco Massari, Vincenzo Di Nunno, Veronica Mollica, Rodolfo Montironi, Liang Cheng, Alessia Cimadamore, Ana Blanca, Antonio Lopez-Beltran

Research output: Contribution to journalReview article

3 Scopus citations

Abstract

Management of metastatic renal cell carcinoma has been enriched by the advent of new therapeutic compounds. The approval of new combination strategies between targeted agents and immune-checkpoint inhibitors as well as the administration of combinations between immune-checkpoint inhibitors has clearly demonstrated significant improvement toward patients' prognosis and other clinical outcomes. Due to the availability of different treatments, the choice between them may be a difficult issue in our clinical practice. We have summarized current knowledge about available treatments focusing on criteria, which may help clinicians to make decisions.

Original languageEnglish (US)
Pages (from-to)1507-1521
Number of pages15
JournalImmunotherapy
Volume11
Issue number17
DOIs
StatePublished - 2019

Keywords

  • atezolizumab
  • avelumab
  • combination strategies
  • immune-checkpoint inhibitors
  • immunotherapy
  • ipilimumab
  • metastatic renal cell
  • nivolumab
  • pembrolizumab
  • renal cell carcinoma

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Fingerprint Dive into the research topics of 'Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice'. Together they form a unique fingerprint.

  • Cite this

    Massari, F., Nunno, V. D., Mollica, V., Montironi, R., Cheng, L., Cimadamore, A., Blanca, A., & Lopez-Beltran, A. (2019). Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice. Immunotherapy, 11(17), 1507-1521. https://doi.org/10.2217/imt-2019-0115